Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2017-02-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
中国证监会行政许可项目审查一次反馈意见通知书
Regulatory Filings Classification · 95% confidence The document is a formal feedback letter from the China Securities Regulatory Commission (CSRC) regarding an administrative licensing project review for a company's application related to issuance of shares to purchase assets. It contains detailed requests for supplementary disclosures, explanations, and opinions from independent financial advisors and lawyers about the transaction and related matters. The document is regulatory in nature, focusing on compliance, legal, and procedural issues rather than presenting financial statements or results. It is not an annual report, audit report, earnings release, or any financial report. It is also not a simple announcement or notice but a regulatory feedback letter requiring a response. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2017-02-27 Chinese
关于收到《中国证监会行政许可项目审查一次反馈意见通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding receipt of a regulatory feedback notice from the China Securities Regulatory Commission (CSRC) related to an administrative licensing project review for a share issuance to purchase assets. It discusses the company's obligation to respond to the regulator within 30 working days and the uncertainty of approval. The document is short (662 characters) and primarily serves as a regulatory update or announcement rather than a detailed financial report or filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention a report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2017-02-27 Chinese
关于限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from 嘉事堂药业股份有限公司 regarding the lifting of restrictions on certain shares (限售股份) and their subsequent listing and circulation on the stock market. It details the number of shares becoming tradable, the shareholders involved, the dates, and the regulatory approvals from the China Securities Regulatory Commission (中国证监会). The document includes specifics about shareholding changes, shareholder commitments, and verification by the sponsoring institution. The content focuses on the change in share status and circulation rather than financial results, management changes, or other report types. The document length is 3039 characters, which is relatively short and is an announcement rather than a full report. This fits the category of Share Issue/Capital Change (SHA), as it concerns the change in capital structure due to the release of restricted shares for trading.
2017-02-26 Chinese
华泰联合证券有限责任公司关于公司限售股份上市流通事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Huatai United Securities regarding the listing and circulation of restricted shares of Jiashitang Pharmaceutical Co., Ltd. It discusses the non-public issuance of shares in 2015, the approval from the China Securities Regulatory Commission, the shareholders involved, the lifting of restrictions on shares, and the changes in share capital structure. The document is a formal verification or audit opinion related to a specific share issuance and circulation event, issued by the sponsor institution. It does not contain financial statements or quarterly/yearly financial results, nor is it a simple announcement or a presentation. It is a standalone audit/verification report on a specific regulatory matter concerning share issuance and circulation. Therefore, it fits best under the category Audit Report / Information (AR). The document length is 3399 characters, which is consistent with a detailed verification opinion rather than a brief announcement or a full annual/interim report. Q1 2017
2017-02-26 Chinese
华泰联合证券有限责任公司关于公司2016年现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled '现场检查报告' which translates to 'On-site Inspection Report'. It is issued by 华泰联合证券有限责任公司 (Huatai United Securities Co., Ltd.) regarding 嘉事堂药业股份有限公司 (Jia Shi Tang Pharmaceutical Co., Ltd.) for the year 2016. The report details the on-site inspection conducted in February 2017 covering the period January to December 2016. It includes detailed findings on company governance, internal controls, information disclosure, use of raised funds, performance, and other important matters. The document is a standalone inspection report by the sponsor institution, not a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on the inspection results. This fits the category of an Audit Report / Information (AR) as it relates to regulatory inspection and compliance findings separate from the full annual report. FY 2016
2017-02-21 Chinese
关于收到中国证监会行政许可申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (537 characters) regarding the receipt of an administrative license application acceptance notice from the China Securities Regulatory Commission (CSRC) related to a major asset restructuring plan. It states that the application materials have been accepted and that the restructuring is subject to further approval, with a caution about investment risks. There is no detailed financial data, no full report, and no detailed analysis. The document is an official regulatory announcement about the status of a regulatory application, not a full report or detailed filing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-02-10 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.